Browsing by Author Hauschild, Axel

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2017Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaKefford, Richard (Rick); Long, Georgina; Atkinson, Victoria; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Hauschild, Axel; Haydon, Andrew; Larkin, J; MandalĂ , Mario; Nyakas, Marta; Santinami, Mario; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1813-1823
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2016Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsKefford, Richard (Rick); Long, Georgina; Carver, Jennifer; Casey, Michelle; Flaherty, Keith; Gagnon, Robert; Goodman, Vicki; Haney, Patricia; Hauschild, Axel; Hwu, Patrick; Legos, Jeffrey J.; Martin, Anne-Marie; Mazumdar, Jolly; O'Hagan, Anne; Santiago-Walker, Ademi; Schadendorf, D; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials, Clinical Cancer Research, vol.22, 3, 2016,pp 567-574
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2017Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyLong, Georgina; De Braud, Filippo; et al, Various; Flaherty, K; Garbe, C; Gogas, Helen; Hauschild, Axel; Jouary, Thomas; Larkin, J; Levchenko, Evgeny; Stroyakovskiy, Daniil; Northern Clinical School: MedicineDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Annals of Oncology, vol.28, 7, 2017,pp 1631-1639
2016Survival of patients with advanced metastatic melanoma: The impact of novel therapiesLong, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: The impact of novel therapies, European Journal of Cancer, vol.53, N/A, 2016,pp 125-134
2017Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Long, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017, European Journal of Cancer, vol.83, N/A, 2017,pp 247-257
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55
2015Treatment algorithms in stage IV melanomaKefford, Richard (Rick); Dummer, R; Eggermont, Alexander; Espinosa, E; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Martin-Algarra, Salvador; Robert, C; Rutkowski, Piotr; Schadendorf, D; Western Clinical School: Westmead Institute for Medical ResTreatment algorithms in stage IV melanoma, American Journal of Therapeutics, vol.22, 1, 2015,pp 61-67